OTIVIDEX® Phase 3 trial results in Ménière’s disease expected by end of February

OTO-313 Phase 2 trial in tinnitus planned to start in first quarter of 2021 with top-line results expected in mid-2022OTO-413 Phase 1/2 trial expansion in hearing loss expected to start in second quarter of 2021 with results anticipated in mid-2022



Takeabreak02-18 12:40

数据要来了,又是一轮攻势,估值太低,MC 270M vs. 1,800M of $Frequency(FREQ)$ , 后者今年以来一个多月已上50%。上到5倍,1.3B合理市值。